Led · Equity · May 2025

Kincell Bio is a scientifically focused CDMO engineering cells into therapies and supporting immune cell programs including autologous and allogeneic CAR‑T, CAR‑NK and CAR‑M, as well as stem cell and iPSC products. Its platform offers personalized, responsive process development and manufacturing from early clinical through pivotal studies and product launch, with services in analytical and process development, GMP manufacturing, testing and release. The company operates manufacturing facilities in Research Triangle Park, NC and Gainesville, FL. Kincell plans to expand its cGMP capabilities and enhance process development services to support emerging cell therapy companies. The recent $22 million investment will accelerate those expansions and support development of innovative solutions tailored to the cell therapy market. Leadership additions, including the appointment of industry veteran Pete Buzy to the board, are positioned to bolster operational expertise as the company scales. Kincell Bio is a CDMO spun out of Inceptor Bio’s CMC, offering analytical development, process development, CMC consulting and early-stage GMP manufacturing for immune cell therapies. The company focuses on autologous and allogeneic CAR-T, CAR-NK and CAR-M programs. Kincell acquired a facility and a fully staffed team at its Gainesville site and plans to grow in Gainesville as well as Research Triangle Park, Boston and other customer locations. The company plans to establish in-house mRNA development and add GMP manufacturing capacity while forging partnerships for viral vector and plasmid DNA supply. Leadership includes CEO Bruce Thompson, Ph.D., who brings over 20 years of CMC strategy and cell therapy manufacturing experience, and board chair Shailesh Maingi of Kineticos Ventures. Kincell emerged from stealth with new funding to support its manufacturing and development expansion.

Participated · Equity · Apr 2024

EnteroBiotix is a clinical-stage biopharmaceutical company focused on full-spectrum microbiome therapeutics. Its lead product, EBX-102-02, is a next-generation full-spectrum microbiome therapeutic manufactured with proprietary processing technologies intended to enable safe, stable, orally delivered microbial ecosystem restoration. The company positions EBX-102-02 as a potential first disease-modifying therapy for IBS-C and advanced the candidate into a Phase 2b program following positive Phase 2a TrIuMPH trial results in 122 patients. The RISE Phase 2b trial is randomized, double-blind, placebo-controlled and plans to enroll around 300 patients in the UK, with first dosing expected in Q2 2026 and topline data due in H2 2027. EnteroBiotix is building a broader pipeline in high-value gastrointestinal indications associated with significant unmet need. EBX-102-02 is not approved for clinical therapeutic use outside of clinical trials or regulated programmes.

Led · Series A · May 2023

eXmoor pharma positions itself as a one-stop cell-and-gene-therapy (CGT) partner, combining GMP manufacturing capability with translation and capital consulting and process and analytical development labs. The company supports clients across CMC strategy and has completed over 500 projects for 150 organizations. eXmoor has specialised in the CGT sector since 2007 and was founded in 2004. It is headquartered in Bristol, UK, and currently employs about 80 people, with a stated plan to grow to 200 employees by 2027. In the announced project with Virica, eXmoor will apply its scale-up process development expertise to optimise AAV vector manufacture from small- through commercial-scale capacity and to deploy validated enhancer formulations for clients. eXmoor pharma provides end-to-end CGT support including translation and capital consulting, process and analytical development labs, and GMP manufacturing capability to accelerate the path from research to patients. Founded in 2004 and specialising in CGT since 2007, the company has completed over 500 projects for 150 organisations. It is led by CEO Angela Osborne and currently employs 80 people, with plans to grow to 200 by 2027. eXmoor is launching a 65,000 sq ft Cell and Gene Therapy Centre in Bristol featuring manufacturing cleanrooms, process and analytical development and QC laboratories, and associated support spaces. The facility is purpose-built to develop and manufacture autologous and allogeneic cell therapies as well as viral vectors. The company recently secured financing to support this expansion.

Participated · Series B · Nov 2022

Experic provides CDMO and clinical trial supply services with capabilities across packaging and finished-dose modalities, including dry powder inhalation (DPI) products. The company operates a state-of-the-art cGMP facility and emphasizes handling of low-dose powders and customer-oriented, white-glove service. Experic offers end-to-end development and manufacturing services intended to accelerate development and commercialization of therapies. The firm said new growth capital will enable enhancement of its manufacturing capabilities and support accelerated international expansion. Management framed the funding as a way to meet growing demand from biopharma customers and to expand technical capabilities. The company is based in Cranbury, N.J., and delivers global clinical trial supply and manufacturing services. Experic provides formulation, development, manufacturing, and analytical services for hard-to-handle powder drug products as well as clinical trial supply and logistics. The company supports every phase of a product’s life cycle from conception to clinical and commercial scale across dosing and packaging formats including tablets, pellets, capsules, and low-dose dry powder inhalation. Experic operates a state-of-the-art Class A cGMP facility in Cranbury, New Jersey. Over the past year it has experienced extraordinary growth in demand for its services. The company emphasizes personalized service and a flexible approach that drives repeat business. Recent capital will be used to expand capabilities, grow the Cranbury facility, hire top talent, and make further capital investments.

Led · Series A · May 2022

Inceptor Bio is a Morrisville, NC-based biotechnology company developing next-generation cell and gene therapy platforms, including CAR-T, CAR-M and CAR-NK. The company focuses on novel mechanisms to enhance cell performance in the tumor microenvironment and to address underserved, difficult-to-treat cancers. Core technologies cited include a co-stimulatory domain M83, the proprietary TMax manufacturing process, the K62 platform to increase macrophage phagocytosis and a differentiated iPSC technology. Inceptor partners with universities, medical centers and industry leaders to advance discovery-phase technologies into Phase I and II clinical assets. Following a $37M Series A led by Kineticos Ventures, the company plans to advance its CAR-T lead into a Phase I clinical trial and continue development of its CAR-M and CAR-NK platforms. Proceeds will also support completion of its Advanced Manufacturing Platform (AMP+), a 29,000 square foot cell and gene therapy GMP manufacturing facility in Gainesville, Florida.